Moderate-to-Vigorous Exercise Can Delay Mortality in Inoperable Lung Cancer
By Lori Solomon HealthDay Reporter
MONDAY, Jan. 8, 2024 -- Higher device-measured moderate- to vigorous-intensity physical activity (MVPA) is associated with reduced 12-month mortality in people newly diagnosed with inoperable lung cancer, according to a study published online Nov. 27 in the Journal of Clinical Medicine.
Vinicius Cavalheri, Ph.D., from Curtin University in Perth, Australia, and colleagues examined device-measured PA and sedentary behavior at the time of diagnosis in people with inoperable lung cancer and investigated PA associations with 12-month mortality. The analysis included 89 participants.
The researchers found that overall, 12-month mortality was 30 percent. However, participants who spent >4.6 minutes/day in MVPA had a lower relative risk of 12-month mortality compared with those who spent ≤4.6 minutes/day in MVPA (hazard ratio, 0.40; 18 versus nine deaths). No other measures of PA/sedentary behavior were associated with 12-month mortality.
"These new findings further indicate that health care providers should investigate a person’s levels of physical activity in early management of inoperable lung cancer," Cavalheri said in a statement. "We also need to evaluate what can be done to encourage people with inoperable lung cancer to exercise more, as 24 percent of the study’s participants engaged in less than one minute per day of moderate-to-vigorous physical activity."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.